On January 24, 2019, the Board of Directors of Provectus Biopharmaceuticals, Inc. pursuant to Section 2, Term of the Independent Contractor Agreement between Interim Chief Financial Officer John Glass and the company, entered into on April 14, 2016 and amended on December 3, 2016, provided Mr. Glass 60-day written notice of the company’s intent to terminate the Agreement. Mr. Glass will continue to serve in his current capacity with the company until the effective date of the termination of the Agreement on March 25, 2019.